EP4670738A3 — Method for stabilizing the ph of an aqueous composition comprising a drug
Assigned to Oculis Operations SARL · Expires 2026-03-04 · 0y expired
What this patent protects
The present disclosure relates to an eye drop formulation comprising 1.5% (w/v) dexamethasone and gamma-cyclodextrin for use a in a method of treating diabetic macular edema (DME) in a human subject in need thereof.
USPTO Abstract
The present disclosure relates to an eye drop formulation comprising 1.5% (w/v) dexamethasone and gamma-cyclodextrin for use a in a method of treating diabetic macular edema (DME) in a human subject in need thereof.
Drugs covered by this patent
- Sandimmune (cyclosporine) · Novartis AG (originally Sandoz)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.